Results 101 to 110 of about 6,879 (203)
The CB1 receptor agonist WIN 55,212-2 fails to evoke physical dependence in Swiss mice
Potential ability of cannabinoids to produce dependence is still a controversial issue. In our study, in order to examine the cannabinoid physical dependence phenomenon we administered CB1 receptor agonist WIN55,212-2, afterwards, in order to ...
Barbara Budzyńska, Grażyna Biała
doaj
Kirk A Bronander1, Michael J Bloch21Division of General Internal Medicine, 2Divisions of Cardiology and General Internal Medicine, Department of Medicine, University of Nevada School of Medicine, Reno, NV, USAAbstract: The endocannabinoid system (ECS) is
Kirk A Bronander, Michael J Bloch
doaj
研究背景 根據近年的基礎研究結果顯示,血管發炎反應在動脈粥狀硬化的病程發生中扮演著相當重要的角色。而在現今可取得的治療藥物當中,口服降血糖劑metformin與抗肥胖劑rimonabant (SR141716),都有研究報告指出其改善病人的整體代謝功能。本篇研究之宗旨在於調查metformin和rimonabant對於血管內皮細胞是否具有抗發炎的功效,以及其中相關的分子機轉。 實驗方法 本篇採用人類臍靜脈內皮細胞,以及TNF-α處理細胞所引起之IL-6生成和NF-κB路徑之活化,作為發炎反應的研究模式,
黃南嵐, Huang, Nan-Lan
core
The structural similarity between an MmpL3 inhibitor BM212, and a cannabinoid receptor modulator rimonabant, prompted us to investigate the anti-tubercular activity of rimonabant and its analogues. Further optimization, particularly through incorporation
Gokhale, Rajesh +9 more
core +1 more source
Rimonabant n,n-dimethylformamide solvate, and method for preparing same
The invention relates to a rimonabant N,N-dimethylformamide solvate, and to a method for preparing the ...
Coquerel, Gérard, Fours, Baptiste
core
Rimonabant: una nueva perspectiva en el tratamiento de las conductas adictivas [PDF]
Se revisa la farmacología, eficacia clínica, farmacocinética, seguridad y lugar en la terapéutica de rimonabant, un nuevo antagonista selectivo de los receptores cannabinoides CB1.Se realizó una revisión de la literatura primaria obtenida en el MEDLINE ...
Bellver, Maria +3 more
core
Rimonabant 2-methoxyethanol solvate and method for preparing same
The invention relates to a rimonabant 2-methoxyethanol solvate, and to a method for preparing the same ...
Coquerel, Gérard, Fours, Baptiste
core
: Aims: Rimonabant, the first selective cannabinoid type 1 receptor blocker, has been shown to produce weight loss and improvements in several cardiometabolic risk factors over 1 year.
Van Gaal, Luc +5 more
core
Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century.
Amir H Sam +2 more
core
Molecular glue mediated degradation of cannabinoid receptor 1 for cancer therapy. [PDF]
Kashkush A +3 more
europepmc +1 more source

